Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Oligometastatic Prostate Carcinoma 1Oligo-metastatic Prostate Carcinoma 1Neoplasms 1Metastatic Hormone-Sensitive Prostate Cance 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 37Oxaliplatin 17Capecitabine 17Irinotecan 15Leucovorin 13HMPL-013 12Fluorouracil 12Cetuximab 11trifluridine tipiracil drug combination 7irinotecan sucrosofate 6tipiracil 5Trifluridine 5Specimen Handling 5Drug Therapy 5tislelizumab 4Standard of Care 4Mitomycin 4Magnetic Resonance Spectroscopy 4Injections 4Folfox protocol 4trametinib 3toripalimab 3pembrolizumab 3Nivolumab 3IFL protocol 3Colonoscopy 3Blood Specimen Collection 3Biopsy 3sotorasib 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Colorectal Neoplasms × abiraterone × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡